Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting
October 05, 2020 07:00 ET
|
Trevena Inc.
-- Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine -- CHESTERBROOK, Pa., Oct. 05, 2020 ...
Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting
September 21, 2020 07:00 ET
|
Trevena Inc.
-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting Posters on OLINVYK benefit-risk profile and TRV250 Phase...
Trevena, Inc. to Present at September Virtual Investor Conferences
September 02, 2020 07:00 ET
|
Trevena Inc.
- H.C. Wainwright: 22nd Annual Global Investment Conference -September 14th - Cantor Fitzgerald Virtual Global Healthcare Conference - September 17th -Oppenheimer Fall Healthcare Life Sciences...
Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine
August 26, 2020 07:00 ET
|
Trevena Inc.
-- Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis Publication in Clinical Drug Investigation:...
Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London
August 24, 2020 07:00 ET
|
Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19 The Company expects to report topline data in Q1...
Trevena Announces Receipt of Milestone Payment Under Partnership in China With Jiangsu Nhwa Pharmaceutical Co.
August 20, 2020 07:36 ET
|
Trevena Inc.
-- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection Additional approval and commercialization milestone payments expected as well as 10% royalties on net sales in...
Trevena to Present at the Virtual JMP Securities CNS Forum
August 14, 2020 13:42 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Trevena Announces Pricing of $50 Million Public Offering of Common Stock
August 12, 2020 09:27 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces Proposed Public Offering of Common Stock
August 11, 2020 16:01 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection
August 10, 2020 06:30 ET
|
Trevena Inc.
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 ...